This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
250mg | $650 | Check With Us |
500mg | $1050 | Check With Us |
1g | $1575 | Check With Us |
Cat #: V2983 CAS #: 1494675-86-3 Purity ≥ 98%
Description: DprE1-IN-1 (AZ-7371; TBA-7371), a 1,4-azaindole analog, is a potent and noncovalent inhibitor of decaprenylphosphoryl-β-d-ribose-2'-epimerase (DprE1) with a potential to become a drug candidate for treatment of tuberculosis. It inhibits DprE1 with ic50 of 10 nM; it also inhibits PDE6 with IC50 of 6 uM. It demonstrats efficacy in a rodent model of tuberculosis, making it promising for further development. DprE1-IN-1 has excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-β-d-ribose-2'-epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. In summary, DprE1-IN-1 is a promising candidate for the development of a novel anti-TB drug.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 355.39 |
---|---|
Molecular Formula | C18H21N5O3 |
CAS No. | 1494675-86-3 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
Solubility In Vitro | DMSO: 11 mg/mLr |
Water: <1 mg/mLr | |
Ethanol: <1 mg/mL | |
SMILES Code | COC1=NC=NC(CN2C=C(C(NCCO)=O)C3=NC=C(C)C=C32)=C1C |
Synonyms | AZ7371; TBA7371; AZ-7371; TBA 7371; AZ 7371; TBA-7371 |
Protocol | In Vitro | In vitro activity: DprE1-IN-1, a 1,4-azaindole analog, is a potent inhibitor of decaprenylphosphoryl-β-d-ribose-2'-epimerase (DprE1) with ic50 of 10 nM; it also inhibits PDE6 with IC50 of 6 uM. It demonstrats efficacy in a rodent model of tuberculosis, making it promising for further development. DprE1-IN-1 has excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-β-d-ribose-2'-epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. In summary, DprE1-IN-1 is a promising candidate for the development of a novel anti-TB drug. Kinase Assay: DprE1-IN-1, a 1,4-azaindole analog, is a potent inhibitor of decaprenylphosphoryl-β-d-ribose-2'-epimerase (DprE1) with ic50 of 10 nM; it also inhibits PDE6 with IC50 of 6 uM. |
---|---|---|
In Vivo | DprE1-IN-1 demonstrats efficacy in a rodent model of tuberculosis, making it promising for further development. The pharmacokinetic profile of DprE1-IN-1 as a representative of the series in mice, rats, and dogs was determined after i.v. and oral dosing. DprE1-IN-1 shows oral bioavailabilities of 86% and 100% in rats and dogs, respectively. The oral exposures of DprE1-IN-1, assessed in infected animals, shows AUCs ranging from 166 to 240 μM · h, and free plasma concentrations were maintained above the MIC for 10 to 24 h. | |
Animal model | Rodent model of tuberculosis | |
Dosages | Oral |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.8138 mL | 14.0691 mL | 28.1381 mL | 56.2762 mL |
5mM | 0.5628 mL | 2.8138 mL | 5.6276 mL | 11.2552 mL |
10mM | 0.2814 mL | 1.4069 mL | 2.8138 mL | 5.6276 mL |
20mM | 0.1407 mL | 0.7035 mL | 1.4069 mL | 2.8138 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.